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Introduction 
Drugs can modify social behavior of patients, and the so-
cial context within which a patient is treated can influence 
a drug's action. Although there is much support for this 
statement from psychiatric experiences, its scientific basis 
is small (cf. Stitzer et al., 1981) and urgently requires fur-
ther research. Up to now, rather isolated groups have tried 
to evaluate the effects of drugs on social behavior, and 
these groups are mainly concerned with the social conse-
quences of drug addiction. To give an example, the Balti-
more group (e.g. Stitzer et aI., 1980) described enhancing 
effects of drugs like d-amphetamine, secobarbital, and 
alcohol on human conversation. Nevertheless, regarding 
most of our (psycho-) pharmacotherapeutic drugs, there 
is little systematic knowledge about their influences on the 
social behavior of drug-treated patients or subjects (cf. 
McGuire et al., 1982). 
Research in this area is hindered especially by the two 
basic problems of either creating suitable experimental 
models of social behavior (lab experiments, e.g. Kriiger and 
Kohnen, 1982) or finding valid methods for evaluating 
social activities in everyday-life settings (field studies). 
Regarding field studies, in this paper a new instrument 
called the LOGOPORT will be introduced for evaluating 
drug-induced changes in talking activities in everyday-life 
conversations. 
Method 
The LOGOPORT is a portable microcomputer. It is connected by 
a cable to a throat microphone which is adhered to the neck of a 
patient or subject. This device enables the researcher to register 
(and computerize) whether a person is speaking or not in a fIxed 
interval (say, 5 seconds) within a considerable space of time (say, 
12 hours). The LOGOPORT data makes it possible to reconstruct 
all talking activities of a person during registration time, especially 
allowing the researcher to identify characteristic parameters of a 
person's conversations. According to Heidenfelder (1985), valid 
LOGOPORT-indicators for interactional social b·~havior are the 
following: (a) the duration of a single talk; (b) a person's involve-
ment in a talk (i.e., the time he or she is speaking within a 
conversation either alone or at the same time as a partner); (c) the 
pause-interval between two consecutive conversations. These para-
meters proved to be suitable for evaluating drug effects on human 
speech (cf. Stitzer et al., 1984). The advantage of the LOGOPORT 
device, compared e.g. to the quite similar procedure of the Balti-
more group (Griffiths et al., 1977), is that the patient or subject 
does not have to stay in the laboratory but can move away into 
his or her fIeld of everyday life. So, highly naturalistic speech 
activities are registered by the LOGOPORT (for more details 
regarding the LOGOPORT, see Kriiger (1985), or write to the 
authors). 
In a fIeld study, the effects of a new compound, CGP 361/A, on 
talking activity were examined using the LOGOPORT. CGP 361/A 
is an experimental drug (Ciba-Geigy, Basel) exerting (>.receptor 
blocking properties in animal studies comparable to those of 
propranolol. Very small dosages (0.3 mg and 0.6 mg per kg p.o.) 
of this drug in monkeys produced enhancing of affiliative behav-
ior: the drug increased grooming contacts, at strongest in animals 
with normally low grooming rates (alpha, omega position in the 
group; Jaekel, 1986). Based on this observation, it was hypothe-
sized that the drug will influence (improve) interactive social 
behavior in man, particularly in socially handicapped people. 
Using the symptomatic volunteer approach (Goldstein and Brau-
zer, 1971), nl = 18 subjects were engaged who described them-
selves as socially handicapped (stressed, with social defIcits, etc.), 
and n2 = 18 subjects were hired who assessed themselves as 
socially successful. Psychometric validation of the subjects' self-
evaluations yielded statistically signifIcant differences (p < 
0.001 %) in measures of assertiveness. The subjects were paid for 
their participation. Half of the subjects in each group were males, 
the age-range was 20 to 30 years with a median of 23 years. In a 
randomized-group design, two dosages of CGP 361/ A (10 mg and 
20 mg p.o.) and placebo were given in a double-blind manner to 
the subjects twice a day (8 a.m. and 6 p.m.) for 4 days. Every 
morning, the subjects were connected with the LOGO PORT and 
left the lab for their normal (campus) activities. In the evening 
(at 6 p.m.), the subjects returned to bring back the LOGOPORT. 
To minimize interindividual differences in social activities, the 
late evening was excluded from inVestigation in this study. After 
termination of the 4-days-period, the LOGOPORT parameters were 
calculated as mean values over 4 days. 
Results 
The LOGOPORT parameters are not normally distributed; 
therefore the data were evaluated statistically by the 
Kruskal-Wallis-Test separately for both groups. There were 
no significant drug - placebo differences in the socially 
successful subjects; however, in the socially handicapped 
group clear distinctions could be made between drug and 
placebo treatment. To clarify the action of CGP 361/A, 
its effects in the socially handicapped people were compa-
red to the effects of placebo treatment in the socially 
successful subjects. 
The two groups differed significantly in their involvement 
in talking under placebo (Figure 1; P < 0.01, Wilcoxon-
Test). As could be expected, socially successful subjects 
were more engaged than SOCially handicapped: the latter 
spent about 47% of the total time speaking and the success 
ful subjects 63%. Drug treatment brings involvement-in-tal-
king measures of the socially handicapped subjects to the 
placebo level of the socially successful subjects: the invol-
vement in talking is about 58% under 10 mg CGP 361/A, 
and is about 63% under 20 mg CGP 361/A. The drug-
placebo difference is highly significant (p < 0.001) in the 
socially handicapped group. 
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Fig. 1 Involvement in talking as percentage of the speech time 
related to the total time of a conversation. 
---: involvement·in·talking level of socially successful subjects 
under placebo treatment; 
--: involvement-in-talking of socially handicapped subjects 
under placebo (PL) and CGP 361/A (10 = 10 mg, 
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Fig. 3 Mean pause-interval between two consecutive talks. 
---: pause-interval of socially successful subjects under placebo 
treatment; 
--: pause-interval of socially handicapped subjects under 
placebo (PL) and CGP 361/A (10=10 mg, 20=20 mg) 
In Figures 2 and 3, quite similar effects of CGP 361/ A on 
the (mean) duration of talks (Fig. 2) and the (mean) inter-
val between two consecutive talks (Fig. 3) are shown. 
Differences between the two groups under placebo (p < 
0.05, Wilcoxon-Test) are whiped out by the drug. The 
mean duration of the talk is lengthened in the socially 
handicapped subjects by both dosages of CGP 361/ A 
(from 14 minutes under placebo ·to 23 rninutesunder both 
dosages, p < 0.05) to the level of the socially successful 
people (22 minutes). The pause-interval between each of 
two talks increases from 33 minutes under placebo to 62 
minutes under 10 mg and to 50 minutes under 20 mg 
CGP 361/A (p < 0.10), while placebo-treated, successful 
subjects have pauses between two talks of 49 minutes. 
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Fig. 2 Mean duration of all conversations. 
20 
---: duration of conversations of socially successful subjects 
under placebo treatment; 
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--: duration of conversations of socially handicapped subjects 
under placebo (PL) and CGP 361/A (10 = 10 mg, 
20 = 20 mg) 
Summarizing the drug-induced changes in LOGOPORT 
parameters, it can be stated that differences in initial level 
of talking activites between socially handicapped and 
socially successful subjects diminish under verum condition. 
The drug effect already appears under the lower dosage of 
10 mg CGP 361/ A. However, in socially successful people, 
the drug hardly affected talking activities at all. 
Discussion 
Socially handicapped subjects are described by the LOGO-
PORT measures as rather hectic people. Compared to the 
behavior of socially successful subjects, their conversations 
are rather short, they are less involved in talking, but they 
start up the next conversation very quickly. These observa-
tions indicate that most conversations are not satisfying 
for the handicapped people and/or their partners, and so 
are finished rather early by one or the other (cf. Kriiger, 
1985). CGP 361/A induces a considerable change in these 
aspects of social behavior. No differences between socially 
successful and socially handicapped subjects appear any 
longer in behavioral measures of talking activities. These 
changes could tentatively be interpreted, according to 
Jaekel (1986), as enhancement of affiliative behavior. Such 
effects may be characterized as "sociotropic" drug effects. 
The mechanism by which CGP 361/A acts on talking 
activities remains unclear. 
The LOGOPORT is a suitable instrument to evaluate non-
verbal characteristics of verbal behavior which is an impor-
tant dimension of human socialness. The LOGOPORT can 
easily be applied in the field of everyday-life withtout any 
considerable problems. 
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